These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3093882)

  • 1. Opioid peptides as drug products: FDA regulatory requirements.
    Hoiberg CP; Rapaka RS
    NIDA Res Monogr; 1986; 70():385-404. PubMed ID: 3093882
    [No Abstract]   [Full Text] [Related]  

  • 2. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critics fear the FDA is going too far in cutting industry's regulatory load.
    Demkovich LE
    Natl J (Wash); 1982 Jul; 14(29):1249-52. PubMed ID: 10255878
    [No Abstract]   [Full Text] [Related]  

  • 6. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interview with FDA Commissioner Frank Young. Interview by Carmella Bocchino.
    Young FE
    Nurs Econ; 1989; 7(5):242-8. PubMed ID: 2812067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA paves the way for drug law reform.
    Eichelberger BM
    Am J Hosp Pharm; 1978 Jul; 35(7):878, 882. PubMed ID: 665706
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA under attack.
    Mod Vet Pract; 1981 Mar; 62(3):197-201. PubMed ID: 7207445
    [No Abstract]   [Full Text] [Related]  

  • 10. How does the FDA affect you and your practice?
    Novitch M
    Leg Aspects Med Pract; 1979 Mar; 7(3):23-6. PubMed ID: 423685
    [No Abstract]   [Full Text] [Related]  

  • 11. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics: regulatory aspects. Point of view of FDA.
    Teske RH; Newkirk DR
    Vet Hum Toxicol; 1990 Jun; 32(3):261-2. PubMed ID: 2353440
    [No Abstract]   [Full Text] [Related]  

  • 13. Desperation drugs. Frustrated AIDs patients are spurring the FDA to relax the rules of the game.
    Begley S; Hager M; Wilson L
    Newsweek; 1989 Aug; 114(6):48-9, 51. PubMed ID: 10293942
    [No Abstract]   [Full Text] [Related]  

  • 14. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiopharmaceuticals and FDA: a clinician's perspective.
    Siegel BA
    Med Instrum; 1981; 15(6):355-60. PubMed ID: 7040923
    [No Abstract]   [Full Text] [Related]  

  • 16. ONS testifies to the FDA about opioid regulation.
    Greenberg L
    ONS Connect; 2009 Jul; 24(7):18. PubMed ID: 19645161
    [No Abstract]   [Full Text] [Related]  

  • 17. Kelsey's Commandos: FDA investigates the investigators.
    Small WE
    Am Pharm; 1979 Jun; 19(6):30-3. PubMed ID: 463736
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a course of study in FDA drug regulatory procedures.
    Jacobs RW; King JC
    Am J Pharm Educ; 1977 May; 41(2):185-88. PubMed ID: 10236647
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA takes action against unapproved drugs.
    Meadows M
    FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.